Progression of Asthma Measured by Lung Function in the Childhood Asthma Management Program
Ronina A. Covar,
Joseph D. Spahn,
James R. Murphy and
Stanley J. Szefler for the Childhood Asthma Management Program Research Group
Ira J. and Jacqueline Neimark Laboratory of Clinical Pharmacology; Department of Pediatrics, Division of Allergy-Clinical Immunology; and Division of Biostatistics, National Jewish Medical and Research Center, Denver, Colorado
Correspondence and requests for reprints should be addressed to Stanley J. Szefler, M.D., National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206. E-mail: szeflers{at}njc.org
From the Childhood Asthma Management Program cohort, which wasrandomly assigned to receive budesonide, nedocromil, or placebofor 46 years, we determined the prevalence of and factorsassociated with at least 1% per year loss in postbronchodilatorFEV1% predicted. Participants who had a significant reductionin postbronchodilator FEV1% predicted (SRP), comprised 25.7%of the cohort (n = 990). Using logistic regression, predictorsof SRP at baseline were younger age (p = 0.0005), male sex (p< 0.0001), clinic (p = 0.02), and higher postbronchodilatorFEV1% predicted (p = 0.02). Examination of the SRPs indicatedthat the effect of baseline lung function was such that thehigher the lung function, the less steep the reduction in postbronchodilatorFEV1% predicted (p < 0.0001). A similar proportion of SRPswas found in each treatment group. Among the SRPs, the rateof reduction in postbronchodilator FEV1% predicted was similarin all treatment groups. At a single site where biomarker assessmentwas performed, SRPs also had more prominent eosinophilic inflammationduring the washout period. The course and mechanisms of lungfunction reduction or slow lung growth velocity in childrenwith asthma must be defined.
J. H. Wildhaber, F. H. Sennhauser, and P. L. P. Brand Asthma in school-aged children and adolescents
Respiratory Diseases in Infants and Children,
July 1, 2010;
191 - 216.
[Abstract][Fulltext][PDF]
S. Guerra and F. D. Martinez Epidemiology of the Origins of Airflow Limitation in Asthma
Proceedings of the ATS,
December 15, 2009;
6(8):
707 - 711.
[Abstract][Full Text][PDF]
A. Bush and A. Menzies-Gow Phenotypic Differences between Pediatric and Adult Asthma
Proceedings of the ATS,
December 15, 2009;
6(8):
712 - 719.
[Abstract][Full Text][PDF]
A. L. James, T. R. Bai, T. Mauad, M. J. Abramson, M. Dolhnikoff, K. O. McKay, P. S. Maxwell, J. G. Elliot, and F. H. Green Airway smooth muscle thickness in asthma is related to severity but not duration of asthma
Eur. Respir. J.,
November 1, 2009;
34(5):
1040 - 1045.
[Abstract][Full Text][PDF]
P G Gibson and J L Simpson The overlap syndrome of asthma and COPD: what are its features and how important is it?
Thorax,
August 1, 2009;
64(8):
728 - 735.
[Abstract][Full Text][PDF]
H. K. Reddel, D. R. Taylor, E. D. Bateman, L.-P. Boulet, H. A. Boushey, W. W. Busse, T. B. Casale, P. Chanez, P. L. Enright, P. G. Gibson, et al. An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations: Standardizing Endpoints for Clinical Asthma Trials and Clinical Practice
Am. J. Respir. Crit. Care Med.,
July 1, 2009;
180(1):
59 - 99.
[Abstract][Full Text][PDF]
E. W. Gelfand Pediatric Asthma: A Different Disease
Proceedings of the ATS,
May 1, 2009;
6(3):
278 - 282.
[Abstract][Full Text][PDF]
P. M. O'Byrne, S. Pedersen, C. J. Lamm, W. C. Tan, W. W. Busse, and on behalf of the START Investigators Group Severe Exacerbations and Decline in Lung Function in Asthma
Am. J. Respir. Crit. Care Med.,
January 1, 2009;
179(1):
19 - 24.
[Abstract][Full Text][PDF]
J. H. Lee, T. Haselkorn, L. Borish, L. Rasouliyan, B. E. Chipps, and S. E. Wenzel Risk Factors Associated With Persistent Airflow Limitation in Severe or Difficult-to-Treat Asthma: Insights From the TENOR Study
Chest,
December 1, 2007;
132(6):
1882 - 1889.
[Abstract][Full Text][PDF]
M. Peters-Golden and W. R. Henderson Jr. Leukotrienes
N. Engl. J. Med.,
November 1, 2007;
357(18):
1841 - 1854.
[Full Text][PDF]
E. H. Walters, D. W. Reid, D. P. Johns, and C. Ward Nonpharmacological and pharmacological interventions to prevent or reduce airway remodelling
Eur. Respir. J.,
September 1, 2007;
30(3):
574 - 588.
[Abstract][Full Text][PDF]
A. L. James and S. Wenzel Clinical relevance of airway remodelling in airway diseases
Eur. Respir. J.,
July 1, 2007;
30(1):
134 - 155.
[Abstract][Full Text][PDF]
S. E. Wenzel and R. Covar Update in asthma 2005.
Am. J. Respir. Crit. Care Med.,
April 1, 2006;
173(7):
698 - 706.
[Full Text][PDF]
P Ernst Inhaled corticosteroids moderate lung function decline in adults with asthma
Thorax,
February 1, 2006;
61(2):
93 - 94.
[Full Text][PDF]
L. R. Choo-Kang Becoming a Complete "Asthmologist"
Chest,
November 1, 2005;
128(5):
3093 - 3096.
[Full Text][PDF]
A. Bush, F. Accurso, W. MacNee, S. C. Lazarus, and E. Abraham Cystic Fibrosis, Pediatrics, Control of Breathing, Pulmonary Physiology and Anatomy, and Surfactant Biology in AJRCCM in 2004
Am. J. Respir. Crit. Care Med.,
March 15, 2005;
171(6):
545 - 553.
[Full Text][PDF]
R. J. Homer and J. A. Elias Airway Remodeling in Asthma: Therapeutic Implications of Mechanisms
Physiology,
February 1, 2005;
20(1):
28 - 35.
[Abstract][Full Text][PDF]
S. Pedersen Progression of Asthma: Small Steps and a Long Way to Go
Am. J. Respir. Crit. Care Med.,
August 1, 2004;
170(3):
206 - 207.
[Full Text][PDF]